Member Info for a4007035

Not really sure why you're looking or worried about the share price. It shouldn't really be a concern if you've done your research and you know the fundamentals of the company.

Funny thing is, it was 900p in June and now its droped by a third in the space of 3 months based on no news whatsoever.

TPG is definitely developing into a beast. Market still remains unconvinced.

Reminds me of Bowser in Mario Kart. Takes a while to get going but unstoppable down the home straight.

Great time to buy at sub 700. Assuming results are in line with the trading update which we have no reason to believe they wont be, the SP will rocket well above 700 once results are announced.

Nah - its just share price manipulation. It dropped below 2p yesterday. And now up by 20%. Do me a favour.

The key to the SP is the profit margins and recoveries that are achieved for each contract and piece of work they do. Winning for revenues is great of course but they will no doubt need to hire further staff, sub contract, etc.

So right now the market are unconvinced over the profit margins for the work that is currently being done.

My prediction is that they won't get the funding that they need. Anyone investing in that funding is merely taking a gamble.

They will run out of cash soon.

Dont forget the power of Leeds United sponsorship in the premier league. This will bring global attention and (correct me if Im wrong) but I cant remember a logistics company being in the PL. Maybe DHL actually.

No it will be about 59 by close of play

IMO - they are still are loss making company. Yes, they win contracts but their internal, administrative, salary costs all add up and they find it difficult to make any reasonable net profit.

https://news.sky.com/story/talktalk-rejected-135p-a-share-bid-from-major-investor-toscafund-12037466

Just got into this SFR. Looks very promising ahead and seems a great price point to buy at. So many projects in the pipeline. Of course some of these will be delayed but the whole business is very diversified in terms of industries/sectors/countries they operate within.

The company has proven incapable of generating any returns.
They will burn through cash and then try to raise more money from shareholders.
I cannot see a single reason why anyone would want to invest here at the present time.

its a 100m swing

What do you think the true value of TPG is?

I agree that it is undervalued especially when you look at the cash balance sheet.

I wouldnt be happy with 10

But tbh I think the market may have been expecting for companies like CLIN to be unaffected by the pandemic or even prosper.

So only a potential of ~90% upside.

Always take broker ratings with a pinch of salt

Its difficult to fully digest the results until we benchmark with other industry competitors to see how everyone else performed in the current economic / Covid 19 environment.

Market reaction is prudent and the previous SP would not have taking into account much of a Covid 19 impact.

Clinigen Group PLC (LON:CLIN) said the 2020 financial year was one of strong organic growth, though the headwinds from the coronavirus lockdown were felt in the final quarter.

In a trading update ahead of the pharma and services company’s September prelims, it said revenues are estimated to have grown by around 17% at constant currencies, or 13% on a gross reported basis for the year to June 30, 2020.

Analysts Clinigen follow closely as a benchmark gross profit, which the group said is expected to have advanced by at least 20% (both on a reported and constant currency basis), or 9% if you strip out the impact of acquisitions.

Underlying earnings (EBITDA), meanwhile, are forecast to have jumped by at least 29% year on year “with organic EBITDA growth ahead of organic gross profit growth”.

In the update, investors were told cash conversion returned to “normal levels” in the second half, with net debt of around £312mln at the period-end, or 2.3-times EBITDA.

Clinigen, which has its own line of specialist treatments as well as providing access to drugs not available in certain markets, reiterated its gross profit growth guidance of 5%-10% over the medium-term.

However, it cautioned that the financial year 2021 is likely to be at the lower end of that range as a result of coronavirus (COVID-19) disruption and the expected launch of a lower-cost ‘generic’ competitor to its antiviral Foscavir in the EU.

Clinigen said it expects the effect of COVID-19 will likely be felt into at least the first quarter of the new financial year. It estimates the financial impact to have been “at least £8mln to EBITDA” in the 12 months just gone, which was “primarily related to Proleukin”, the company’s cancer treatment.

"We continue to see organic growth in line with our medium-term guidance at this early stage of the new financial year, despite COVID-19 and expected competitive pressure to Foscavir,” Clinigen chief executive Shaun Chilton said in the statement

“As we look beyond the financial year 2021, we see growth significantly accelerating as we onboard new asset Erwinase and we continue to gain share in the end-markets we serve," he added.